Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001079973-25-000383 0002060465 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 03/06/2025 false 0001854270 81726A209 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco CA 94080 Lin-Chun Huang 852 3851 8700 Celadon Partners SPV 24 PO Box 500, 71 Fort Street, Grand Cayman E9 KY1-1106 Scott Lesmes 202-887-1500 c/o Morrison & Foerster LLP 2100 L Street, NW #900 Washington DC 20037 0002060465 N Celadon Partners SPV 24 OO N E9 0.00 9777000.00 0.00 9777000.00 9777000.00 N 37.6 OO Y Celadon Partners, LLC OO N E9 0.00 9777000.00 0.00 9777000.00 9777000.00 N 37.6 OO Common Stock, par value $0.0001 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco CA 94080 This Amendment No. 1 ("Amendment No. 1") to Schedule 13D amends the Schedule 13D originally filed on March 13, 2025 (the "Schedule 13D") relating to the Common Stock of the Issuer. Unless otherwise defined herein, all capitalized terms used herein shall have the meanings given to them in the Schedule 13D. This Amendment No. 1 is being filed solely to provide Appendix A referenced in Item 2(d) of the Schedule 13D. No other information is being amended. Celadon Partners SPV 24 /s/ David Egglishaw David Egglishaw, Manager, Celadon Partners, LLC (as sole manager of Celadon Partners SPV 24) 03/17/2025 Celadon Partners, LLC /s/ David Egglishaw David Egglishaw, Manager 03/17/2025